Prazma CM, Idzko M, Douglass JA, et al. - Researchers undertook this post hoc, subgroup analysis to compare the impact of mepolizumab across different atopic phenotypes as well as baseline blood eosinophil count categories in patients from the MENSA study (a multicenter, randomized, double-blind, placebo-controlled trial). Mepolizumab (75 mg intravenously or 100 mg subcutaneously) or placebo, plus standard of care, was administered every 4 weeks for 32 weeks in patients aged ≥ 12 years suffering from severe eosinophilic asthma. The annualized rate of clinically significant exacerbations as well as alteration from baseline in Asthma Control Questionnaire-5 score, were evaluated. Findings revealed that a trend for decreases in clinically significant exacerbations and improved asthma control was offered by mepolizumab vs placebo in patients with severe eosinophilic asthma, regardless of atopic status or house dust mite sensitivity.